

## Loncastuximab tesirine

Cat. No.:	HY-P99349
CAS No.:	1879918-31-6
Target:	Antibody-Drug Conjugates (ADCs); Apoptosis
Pathway:	Antibody-drug Conjugate/ADC Related; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirine induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma <sup>[1][2]</sup> .
<b>In Vitro</b>	Loncastuximab tesirine reduces cell viability and induces apoptosis of three human-derived, CD19 and CD79b-positive NHL cell lines (WSU-DLCL2, TMD8 and Ramos) and shows better effects with the combination of polatuzumab vedotin <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Loncastuximab tesirine (0.25 or 0.5 mg/kg; single dose) shows anti-tumor effects in WSU-DLCL2 xenograft models <sup>[1]</sup> . Loncastuximab tesirine (0.33, 0.66, and 1 mg/kg; i.v. single dose) shows dose-dependently antitumor activity in Ramos xenograft models <sup>[2]</sup> . Loncastuximab tesirine (0.1 and 0.3 mg/kg; i.v. single dose) shows dose-dependently antitumor activity in CD19-expressing Daudi xenograft models <sup>[2]</sup> . Loncastuximab tesirine (0.3 and 1 mg/kg; i.v. single dose) results in significant, dose-dependent extension of survival in WSU-DLCL2 xenograft mouse models <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Nikoleta Sachini, et al. Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma. *Blood*. 2021.

[2]. Zammarchi F, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. *Blood*. 2018 Mar 8;131(10):1094-1105.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA